Result of General Meeting
Genflow Biosciences Plc announced that all resolutions were passed at its General Meeting, with shareholders overwhelmingly approving the Director's authority to allot securities by 98.2% and disapplying statutory pre-emption rights by 97.1%. These approvals, with 224,571,419 votes for the first resolution and 222,245,570 votes for the second, grant the company significant flexibility in managing its capital structure and future fundraising activities.
Select text to share a quote on X · sign in to keep highlights & notes in your GENF notes
Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company focusing on longevity, is pleased to announce that all resolutions proposed at the General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.
Proxy Voting Results
| Ordinary Resolutions | Votes for | % of votes cast for | Votes Against | % of votes cast against | Votes withheld | Total votes cast |
|---|---|---|---|---|---|---|
| 1. To approve the Director's authority to allot securities. | 224,571,419 | 98.2% | 3,787,114 | 1.7% | 429,987 | 228,788,520 |
| Special Resolution | Votes for | % of votes cast for | Votes Against | % of votes cast against | Votes withheld | Total votes cast |
| 2. To disapply statutory pre-emption rights. | 222,245,570 | 97.1% | 5,141,463 | 2.2% | 1,401,487 | 228,788,520 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.